Safety profile of upadacitinib in patients at risk of cardiovascular disease: integrated post hoc analysis of the SELECT phase III rheumatoid arthritis clinical programme.

"Competing interests: RF: research grants and consulting fees from AbbVie, Amgen, AstraZeneca, Biogen, BMS, Boehringer-Ingleheim, Flexion, Galapagos, Galvani, Genentech, Gilead, GSK, Janssen, Lilly, Novartis, Pfizer, Roche, Sanofi-Aventis and UCB. JRC: consulting fees and research support from AbbVie, Amgen, Bristol Myers Squibb, Janssen, CorEvitas, Lilly, Novartis, Myriad, Sanofi, Pfizer and UCB. CC-S: research grants from AbbVie, BMS, CSL Behring and Pfizer; consultancy for AbbVie, Priovant Therapeutics, Octapharma, BMS, Pfizer, Gilead and Regeneron-Sanofi. EFM: research grants and consulting fees from AbbVie, Amgen, Astra Zeneca, Novartis, Lilly, Pfizer, Roche, BMS, Sandoz, GSK, Janssen and Sanofi. KY: consultancy fees from AbbVie, Pfizer, Gilead G.K., Asahi Kasei Pharma, Astellas Pharma, Eli Lilly Japan and Japan Tobacco; member of the speaker’s bureau at Astellas, Bristol Myers Squibb, Chugai, Eisai, Eli Lilly Japan, GlaxoSmithKline, Janssen, Mitsubishi-Tanabe Pharma, Pfizer and Takeda; and research funding from Bristol Myers Squibb, Chugai, GlaxoSmithKline and Mitsubishi-Tanabe Pharma. CR: consultancy and speaking fees from Amgen, AstraZeneca, Roche, BMS, Galapagos, GSK, Lilly, Hospira, Biogen, Sandoz, Mylan, Novartis and Pfizer. GRB: speaking or consulting fees from AbbVie, BMS, Lilly, Galapagos, Janssen, MSD, Pfizer, Roche, Sanofi and UCB. JL, HP, DD and SS: AbbVie employees and may own stocks or options."

"Funding: AbbVie funded the study and had a role in the study design, data collection, data analysis, data interpretation and writing of the report."

"Trial registration numbers NCT02706873, NCT02675426, NCT02629159, NCT02706951, NCT02706847 and NCT03086343."